

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
	09/890,552	08/02/2001	Hideakira Yokoyama	0020-4883P	4627
	2292	7590 01/23/2004		EXAM	INER
	BIRCH STEV	WART KOLASCH & E	BIRCH	JAGOE, DONNA A	
	PO BOX 747	CH, VA 22040-0747		ART UNIT	PAPER NUMBER
	TALLS CHORCH, VII 220 to 07 17			1614	
•				DATE MAIL ED. 01/22/200	4

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No.	Applicant(s)	
09/890,552	YOKOYAMA ET AL.	
Examiner	Art Unit	
Donna Jagoe	1614	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 18 November 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

	PERIOD FOR REPLY [check either a) or b)]
a) 🗌 b) 🗵	The period for reply expiresmonths from the mailing date of the final rejection. The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In one event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP
e have	706.07(f). ensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension are 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or

fee have fee under (2) as se	Proc.or(t). The date on which the petition under 37 CFR 1.136(a). The date on which the petition under the period of extension and the corresponder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period of the correspondent forth in (b) above, if checked. Any reply received by the Office later than three months after the may reduce any earned patent term adjustment. See 37 CFR 1.704(b).	for reply originally set in the final Office action; or						
1. 🛛 7	1. A Notice of Appeal was filed on <u>17 December 2003</u> . Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.							
2. 🔲 1	2. The proposed amendment(s) will not be entered because:							
(a)	they raise new issues that would require further consideration and/or s	earch (see NOTE below);						
(b)	b) they raise the issue of new matter (see Note below);							
(c)	they are not deemed to place the application in better form for appeal issues for appeal; and/or							
(d)	they present additional claims without canceling a corresponding num	ber of finally rejected claims.						
	NOTE:							
	Applicant's reply has overcome the following rejection(s):	* * * * * * * * * * * * * * * * * * * *						
4 N	Newly proposed or amended claim(s) would be allowable if submitte canceling the non-allowable claim(s).	d in a separate, timely filed amendment						
5. 🖾 🗆	5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.							
	6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.							
7. For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.								
٦	The status of the claim(s) is (or will be) as follows:							
	Claim(s) allowed:	PRIMARY EXAMINER						
	Claim(s) objected to:	690H8 4KB3						
	Claim(s) rejected: <u>11-13, 17, 19, 20-21</u> .	andle						
	Claim(s) withdrawn from consideration:							
8. 🔲 -	The drawing correction filed on is a) \square approved or b) \square disappro	ved by the Examiner.						
9. 🗆 1	Note the attached Information Disclosure Statement(s)(PTO-1449) Paper	No(s)						
10. Other:								
. •••								

Continuation of 5. does NOT place the application in condition for allowance because: Goebel et al teach that essential oils, especially peppermint oil to alleviate headache due to a long lasting cooling effect on the skin caused by steric alteration of the calcium channels of the cold-receptors and it's inhibition of 5HT and substance P-induced smooth muscle contraction. It is also known that peppermint oil increases the skin blood flow. A significant analgesic effect with reduction on sensitivity to headache was produced by a combination of peppermint oil and ethanol (an alcohol) Davis et al. teach menthol is a secondary alcohol obtained naturally from peppermint or other mint oils or by synthetic means. Davis further discloses that menthol has many uses as an ingredient in various medicinal preparations due to its analgesic, local anesthetic and counter irritant properties. It is also known to enhance the percutaneous transfer of systemically active drugs in mammals. It would have been obvious to one of ordinary skill in the art to combine the above agents to make a composition that is effective in relieving headache pain..